家族性高胆固醇血症
Familial hypercholesterolemia.
作者信息
Bouhairie Victoria Enchia, Goldberg Anne Carol
机构信息
Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, Campus Box 8127, 660 South Euclid, St Louis, MO 63110, USA.
Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, Campus Box 8127, 660 South Euclid, St Louis, MO 63110, USA.
出版信息
Cardiol Clin. 2015 May;33(2):169-79. doi: 10.1016/j.ccl.2015.01.001.
Abstract
Familial hypercholesterolemia is a common, inherited disorder of cholesterol metabolism that leads to early cardiovascular morbidity and mortality. It is underdiagnosed and undertreated. Statins, ezetimibe, bile acid sequestrants, niacin, lomitapide, mipomersen, and low-density lipoprotein (LDL) apheresis are treatments that can lower LDL cholesterol levels. Early treatment can lead to substantial reduction of cardiovascular events and death in patients with familial hypercholesterolemia. It is important to increase awareness of this disorder in physicians and patients to reduce the burden of this disorder.
摘要
家族性高胆固醇血症是一种常见的遗传性胆固醇代谢紊乱疾病，可导致早期心血管疾病的发病和死亡。该病目前诊断不足且治疗不充分。他汀类药物、依折麦布、胆汁酸螯合剂、烟酸、洛美他派、米泊美生和低密度脂蛋白（LDL）分离术是能够降低LDL胆固醇水平的治疗方法。早期治疗可显著降低家族性高胆固醇血症患者的心血管事件和死亡风险。提高医生和患者对该疾病的认识对于减轻这种疾病的负担至关重要。
相似文献
1
Familial hypercholesterolemia.家族性高胆固醇血症
Cardiol Clin. 2015 May;33(2):169-79. doi: 10.1016/j.ccl.2015.01.001.
2
Familial Hypercholesterolemia.家族性高胆固醇血症
Endocrinol Metab Clin North Am. 2016 Mar;45(1):1-16. doi: 10.1016/j.ecl.2015.09.001.
3
[Severe familial hypercholesterolemia treatment].[重度家族性高胆固醇血症的治疗]
Vnitr Lek. 2016 Fall;62(11):895-901.
4
Modern Management of Familial Hypercholesterolemia.家族性高胆固醇血症的现代管理
Metab Syndr Relat Disord. 2016 Dec;14(10):463-467. doi: 10.1089/met.2016.29011.due. Epub 2016 Oct 31.
5
Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.纯合子家族性高胆固醇血症的诊断与治疗挑战
Drugs. 2015 Oct;75(15):1715-24. doi: 10.1007/s40265-015-0466-y.
6
The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.依折麦布对接受低密度脂蛋白单采治疗的纯合子家族性高胆固醇血症患者血清脂质和脂蛋白的影响。
Atherosclerosis. 2006 May;186(1):126-31. doi: 10.1016/j.atherosclerosis.2005.06.039. Epub 2005 Jul 25.
7
Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.两名家族性高胆固醇血症患者在接受依洛尤单抗治疗后成功停用低密度脂蛋白分离术。
Intern Med. 2017;56(12):1531-1535. doi: 10.2169/internalmedicine.56.7958. Epub 2017 Jun 15.
8
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.洛美他派的降脂作用不受纯合子家族性高胆固醇血症患者辅助性血液成分单采的影响——一项3期单臂开放标签试验的事后分析
Atherosclerosis. 2015 Jun;240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014. Epub 2015 Mar 14.
9
Lipoprotein apheresis.脂蛋白分离术
Cardiol Clin. 2015 May;33(2):197-208. doi: 10.1016/j.ccl.2015.02.002.
10
The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.洛美他派对家族性高胆固醇血症患者心血管结局指标的影响：模型分析。
Eur J Prev Cardiol. 2017 Nov;24(17):1843-1850. doi: 10.1177/2047487317730473. Epub 2017 Sep 19.
引用本文的文献
1
Association between the risk of relative energy deficiency in sport and cholesterol levels in Finnish endurance athletes.芬兰耐力运动员运动中相对能量缺乏风险与胆固醇水平之间的关联
BMJ Open Sport Exerc Med. 2025 Sep 1;11(3):e002644. doi: 10.1136/bmjsem-2025-002644. eCollection 2025.
2
Efficacy and safety of tafolecimab in Chinese patients with familial hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials.他伏利单抗在中国家族性高胆固醇血症患者中的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Ann Med Surg (Lond). 2025 Jul 22;87(9):5990-5998. doi: 10.1097/MS9.0000000000003623. eCollection 2025 Sep.
3
Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study.具有奠基者效应和高糖尿病患病率的杂合子家族性高胆固醇血症中的葡萄糖代谢：一项横断面研究
Cardiovasc Diabetol. 2025 Aug 6;24(1):322. doi: 10.1186/s12933-025-02857-8.
4
Implementing a specialized cardiogenomics team for lipid disorders: Insights from a single large health system.为脂质紊乱患者组建专业的心源基因组学团队：来自一个大型医疗系统的见解
Am J Prev Cardiol. 2025 Jul 19;23:101066. doi: 10.1016/j.ajpc.2025.101066. eCollection 2025 Sep.
5
Management of Pregnancy in a Patient with Familial Hypercholesterolemia and Previous Myocardial Infarction-Treatment with LDL Apheresis: A Case Report.家族性高胆固醇血症合并既往心肌梗死患者的妊娠管理——低密度脂蛋白去除术治疗：一例报告
Reports (MDPI). 2024 May 19;7(2):39. doi: 10.3390/reports7020039.
6
The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk.英克西兰对心血管高危患者动脉粥样硬化性心血管疾病亚临床炎症标志物的影响。
Pharmaceuticals (Basel). 2025 Jun 1;18(6):832. doi: 10.3390/ph18060832.
7
Design of lipid nanoparticle (LNP) containing genetic material CRISPR/Cas9 for familial hypercholesterolemia.用于家族性高胆固醇血症的含基因材料CRISPR/Cas9的脂质纳米颗粒（LNP）设计
Narra J. 2025 Apr;5(1):e2217. doi: 10.52225/narra.v5i1.2217. Epub 2025 Apr 15.
8
Transition of care from childhood/adolescence to adulthood in familial hypercholesterolemia.家族性高胆固醇血症患者从儿童期/青少年期到成年期的护理过渡
J Pediatr Endocrinol Metab. 2025 May 6. doi: 10.1515/jpem-2025-0127.
9
Recurrent Spontaneous Coronary Artery Dissection as the Cause of Repeated Myocardial Infarctions.复发性自发性冠状动脉夹层作为反复心肌梗死的病因
Clin Case Rep. 2025 Jan 10;13(1):e70083. doi: 10.1002/ccr3.70083. eCollection 2025 Jan.
10
Targeted NGS Revealed Pathogenic Mutation in a 13-Year-Old Patient with Homozygous Familial Hypercholesterolemia: A Case Report.靶向 NGS 揭示 13 岁同型家族性高胆固醇血症患者的致病性突变：一例报告。
Int J Mol Sci. 2024 Nov 5;25(22):11882. doi: 10.3390/ijms252211882.
本文引用的文献
1
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.纯合子家族性高胆固醇血症：临床医生提高检测和临床管理水平的新见解与指南。欧洲动脉粥样硬化学会家族性高胆固醇血症共识小组的立场文件。
Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.
2
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.亲历前蛋白转化酶枯草溶菌素9的探索历程：从家族性高胆固醇血症中一种新基因的发现到一类潜在新型抗胆固醇药物的诞生
Curr Atheroscler Rep. 2014 Sep;16(9):439. doi: 10.1007/s11883-014-0439-8.
3
Familial hypercholesterolemia: A review.家族性高胆固醇血症：综述
Ann Pediatr Cardiol. 2014 May;7(2):107-17. doi: 10.4103/0974-2069.132478.
4
Lipid lowering in liver and chronic kidney disease.降脂治疗在肝脏和慢性肾脏病中的应用。
Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):339-52. doi: 10.1016/j.beem.2013.11.006. Epub 2013 Dec 2.
5
An assessment by the Statin Muscle Safety Task Force: 2014 update.他汀类药物肌肉安全性工作组评估：2014 年更新。
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S58-71. doi: 10.1016/j.jacl.2014.03.004.
6
An assessment by the Statin Liver Safety Task Force: 2014 update.他汀类药物肝安全性工作组评估：2014 年更新。
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S47-57. doi: 10.1016/j.jacl.2014.02.011.
7
A clinician's guide to statin drug-drug interactions.他汀类药物药物相互作用的临床医师指南。
J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S30-46. doi: 10.1016/j.jacl.2014.02.010.
8
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation.国际家族性高胆固醇血症基金会关于家族性高胆固醇血症护理的综合指导。
J Clin Lipidol. 2014 Mar-Apr;8(2):148-72. doi: 10.1016/j.jacl.2014.01.002. Epub 2014 Jan 16.
9
Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.洛美他派和米泊美生：用于降低纯合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的两种首创药物。
Circulation. 2014 Mar 4;129(9):1022-32. doi: 10.1161/CIRCULATIONAHA.113.001292.
10
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.荷兰常染色体显性遗传高胆固醇血症的纯合子：患病率、基因型-表型关系和临床结局。
Eur Heart J. 2015 Mar 1;36(9):560-5. doi: 10.1093/eurheartj/ehu058. Epub 2014 Feb 28.
Zotero 插件